Rainbow Seed Fund

Rainbow Seed Fund

The Rainbow Seed Fund is a £24m, early-stage venture capital fund dedicated to kick-starting promising technology companies developed at some of the UK’s largest publicly-funded research facilities.  These companies are linked to the rapidly expanding science and technology campuses and the field of synthetic biology.

Created in 2002, the Rainbow Seed Fund is backed by ten UK publicly-funded research organisations and the Department of Business, Innovation and Skills (BIS). The Fund holds investments in some of the UK’s most innovative companies in areas as diverse as novel antibiotics, research into Alzheimer’s disease, “green” chemicals and airport security.

 

Rainbow Seed Fund Investments

We’re prepared to invest early and help build a commercial proposition around a technology to attract additional investment needed to get to market.

The Rainbow Seed Fund invests in:

1. Projects and companies arising from the world-class research carried out in our Partner laboratories across the UK, including those at Rutherford Appleton Laboratory (STFC), Porton Down (Dstl) and Babraham Institute (BBSRC).  View full list of partners.

2. Companies based at our partners’ national science and innovation campuses in Oxford, Cambridge, Warrington and Norwich. Read more about partner campuses.


Babraham-Research-Campus-smallHarwell-Oxford  Sci Tech Daresbury 2Norwich Research

3. Companies working in the field of synthetic biology:  Synthetic biology is an exciting new discipline based on the design and engineering of biologically-based parts, novel devices and systems and the redesign of existing, natural biological systems.

 

Rainbow Seed Fund Milestones

Over the past decade, the Rainbow Seed Fund has:

  • Supported 30+ technology start-up companies in sectors such as health, environmental services, international development, and security and defence.
  • Leveraged more than £150 million of private investment from just £7 million of its own investment (a ratio of over £20 for every £1 from Rainbow).
  • Bolstered the UK’s exports and employment — 75%-100% of Rainbow Seed Fund company sales are overseas and our companies have created 170+ high-value, technology jobs.
  • In recognition of these achievements, in November 2013 the Rainbow Seed Fund received an additional £10M investment to support the commercialisation of synthetic biology technologies. This funding was in response to the Synthetic Biology Roadmap, which sets out plans to harness opportunities in the field of synthetic biology. Synthetic biology is one of the eight great technologies highlighted by the UK government as an area of wide-ranging significance and potential economic importance, and in which the UK’s research base is particularly strong.

 

Additional Background

 

Rainbow Seed Fund Partners

Partners

The Rainbow Seed Fund is independently managed by Dr. Andrew Muir and Mark White at Midven.

Fund Facts

Current As At: 31st January 2016

Fund Amount 24m

4 Profitable Exits

30 Companies

Fund Managers

Associated Investments

Watch

Relevant News

Crescendo Biologics Appoints Dr Barbara Fleck as Head of Intellectual Property

Cambridge, UK: 2 February 2016 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer…

read more

Contego Announces Selection Into Accenture's Fintech Innovation Lab London

Contego CEO Adrian Black is looking forward to working in the collaborative environment at Level39…

read more

Crescendo Biologics Appoints Dr Kevin Johnson as Chairman

Antibody veteran joins new CEO as Crescendo redirects strategy to Oncology focus  Cambridge, UK: 17…

read more

Crescendo Biologics Launches New Strategy In Oncology Drug Discovery & Development

Crescendo Biologics Limited, the drug discovery and developer of Humabody™ VH therapeutics, has announced the…

read more

Case Studies

Case Study - Cobalt

Summary: Cobalt's innovation technology can identify substances inside opaque glass and plastic containers rapidly with…

read more

Case Study - ZuvaSyntha Ltd

Summary: ZuvaSyntha is developing proprietary renewable manufacturing routes to industrial chemicals from low cost feedstocks…

read more